Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | A Phase II study of ruxolitinib with chemotherapy in pediatric patients with Ph-like ALL

Sarah Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, shares some insights into the Phase II AALL1521 trial (NCT02723994), which is evaluating whether the addition of ruxolitinib to chemotherapy may improve outcomes for pediatric patients with Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Aleta Biotherapeutics: Consultancy; Beam Therapeutics: Research Funding; bluebird bio: Consultancy; Syndax Pharmaceuticals: Consultancy; Kura Oncology: Consultancy, Research Funding; GSK: Consultancy; Incyte Corporation: Research Funding.